Infections remain the Achille's heel of surgical implantation of medical devices and artificial organs. Although the overall incidence of implant infections and their complications can be reduced by the development of new infection-resistant materials and new antimicrobial strategies, the health and social costs of these infections are still high.
The increase in the practice of medical implants has coincided with an increase in nosocomial infections, rising to two million cases annually in the United States alone. The presence of an indwelling medical device has been found to be a critical risk factor, accounting for approximately 45% of all nosocomial infections. The infection rate for or thopedic replacements alone is approaching 2.5%, yelding 25,000 cases of orthopedic implant failure per year. The health and social costs of implant infections with osteomyelitis are serious, often necessitating amputation or extremely wide excision with complex reconstructive surgery.
This issue of IJAO is devoted to a focus on implant associated infections from different points of view, and the hope is that this subject may be developed in the future in further issues with the aim of covering all aspects of implant infections, from etiology and pathogenesis, to prevention and therapy.
Advances in bioengineering have produced exceptional growth in the use of indwelling medical devices, from "simple", such as catheters and stents, to "complex", such as implantable cardiodefibrillators and left ventricular assist devices.
The use of these various medical devices has brought about great progress in the treatment of many medical and surgical conditions. However, many microorganisms are able to adhere to implant surfaces and colonize on them where they can form biofilms that often lead to persistent infections.
This ability to form biofilms is commonly considered a virulence factor for several pathogens, among which staphylococci, Candida and enterococci. The knowledge about the molecular mechanisms involved in biofilm formation is increasing but is not yet exhaustive.
The present issue focuses on the adhesion mechanisms of bacteria to implant surface and devotes great attention to the role of the biofilm in the early stages of infection.
Besides biofilm as a mechanism for bacterial adhesion, the extracellular matrix proteins of the host deserve particular attention. Bacterial MSCRAMMs (Microbial Surface Components Recognizing Adhesive Matrix Molecules) are a variform family of bacterial cell surface protein adhesins that recognize and bind specific extracellular matrix components such as fibrinogen, collagen, and fibronectin within host tissues. Binding of MSCRAMMs to distinct matrix proteins facilitates bacterial attachment, thereby allowing colonization and invasion of the host tissues. A number of micro-organisms that cause device-related infections has been shown to express MSCRAMMs proteins, most notably, staphylococci, streptococci, enterococci, and Candida albicans.
The increasing knowledge on the mechanisms of bacterial adhesion to indwelling medical devices necessarily leads to new concepts and new strategies for therapy.
A very innovative approach is derived from nanotechnology.
The old and fascinating idea of a "magic bullet" in pharmaceutical therapy has stimulated a variety of research since it was brought up by Paul Ehrlich in the early 20 th century. Ehrlich's central conception rests on the search for possible specific drug targeting. An approach close to the original intention may now be found in the applications of nanocapsules loaded with an active drug. These particles should be small enough to pass through the capillary system, should consist of non-toxic and biodegradable material and must combine suitable release and targeting properties.
A special therapeutic application of nanocapsules may be used in connection with implant infections, especially if the infection is connected to the presence of a biofilm. The capsule surface may specifically interact with the polymer framework of the biofilm and if these interactions are selective enough, they may allow for a local accumulation of the capsules on the biofilm surface. Finally, the biological decomposition of the capsule wall will lead to a local release of the capsule contents. If the capsules are loaded with suitable active ingredients, this leads to an efficient drug delivery to the infected interface and could initiate new approaches to treat implant infections.
A different, also innovative approach is to aim for a staphylococcal vaccine. Many studies have the target to
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The arrival of new models of treatment for acute infectious diseases is on the horizon. The use of biological therapies (monoclonal antibodies) in combination with chemotherapeutics for the treatment of certain types of cancers is clinically accepted. However, innovative therapy for the treatment of nosocomial infections is just starting to be explored. The possibility of antibodies synergizing with antibiotics or, in the future, treatments that inhibit the transcription of biofilm controlling genes, could extend the therapeutic options available to the clinician, reduce the duration of therapy, and significantly impact health-care costs.
